Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Apr 15;101(8):1797–1804. doi: 10.1172/JCI1486

Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3).

A E Lovett-Racke 1, P Bittner 1, A H Cross 1, J A Carlino 1, M K Racke 1
PMCID: PMC508763  PMID: 9541512

Abstract

Insulin-like growth factor (IGF)-1 is a cytokine that promotes oligodendrocyte development and myelin production. This study investigated whether treatment of chronic, relapsing murine experimental autoimmune encephalomyelitis (EAE) with IGF-1 or IGF-1 associated with its binding protein, IGFBP3, altered the course of disease. Administration of IGF-1/IGFBP3 (1-100 mg/kg per day) delayed the onset of disease in a dose-dependent manner and histologic examination showed a delay in inflammatory cells entering the central nervous system. However, once signs of EAE developed, disease was enhanced in the mice that had been given the highest dose of IGF-1/IGFBP3. Treatment with IGF-1/IGFBP3 after the onset of signs resulted in a severe relapse. Administration of free IGF-1 (10 mg/kg per day) provided mild protection when given before disease onset, but did not significantly alter the course of disease if given after disease onset. Possible mechanisms that could explain the altered disease in IGF-1/IGFBP3-treated mice included (a) IGF-1/IGFBP3 administration delayed the onset of EAE by downregulating ICAM-1 gene expression in the central nervous system, and (b) IGF-1/IGFBP3 treatment of EAE resulted in more severe disease due to enhanced expansion of encephalitogenic T cells. Although IGF-1 may enhance remyelination, these results indicate that administration of IGF-1 associated with IGFBP3 may also accentuate autoimmune demyelinating disease.

Full Text

The Full Text of this article is available as a PDF (364.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acha-Orbea H., Mitchell D. J., Timmermann L., Wraith D. C., Tausch G. S., Waldor M. K., Zamvil S. S., McDevitt H. O., Steinman L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 1988 Jul 15;54(2):263–273. doi: 10.1016/0092-8674(88)90558-2. [DOI] [PubMed] [Google Scholar]
  2. Adams S., Moore J., Chu S., Bagi C., DeLeon L., Liu C., Schmidt D., Sommer A. Pharmacokinetics and bioavailability of rhIGF-I/IGFBP-3 in the rat and monkey. Prog Growth Factor Res. 1995;6(2-4):347–356. doi: 10.1016/0955-2235(95)00003-8. [DOI] [PubMed] [Google Scholar]
  3. Baron J. L., Madri J. A., Ruddle N. H., Hashim G., Janeway C. A., Jr Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med. 1993 Jan 1;177(1):57–68. doi: 10.1084/jem.177.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beck K. D., Powell-Braxton L., Widmer H. R., Valverde J., Hefti F. Igf1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron. 1995 Apr;14(4):717–730. doi: 10.1016/0896-6273(95)90216-3. [DOI] [PubMed] [Google Scholar]
  5. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 1996 Jan 25;379(6563):343–346. doi: 10.1038/379343a0. [DOI] [PubMed] [Google Scholar]
  6. Cannella B., Cross A. H., Raine C. S. Upregulation and coexpression of adhesion molecules correlate with relapsing autoimmune demyelination in the central nervous system. J Exp Med. 1990 Nov 1;172(5):1521–1524. doi: 10.1084/jem.172.5.1521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carson M. J., Behringer R. R., Brinster R. L., McMorris F. A. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron. 1993 Apr;10(4):729–740. doi: 10.1016/0896-6273(93)90173-o. [DOI] [PubMed] [Google Scholar]
  8. Clark R., Strasser J., McCabe S., Robbins K., Jardieu P. Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin Invest. 1993 Aug;92(2):540–548. doi: 10.1172/JCI116621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cohick W. S., Clemmons D. R. The insulin-like growth factors. Annu Rev Physiol. 1993;55:131–153. doi: 10.1146/annurev.ph.55.030193.001023. [DOI] [PubMed] [Google Scholar]
  10. Cross A. H., Girard T. J., Giacoletto K. S., Evans R. J., Keeling R. M., Lin R. F., Trotter J. L., Karr R. W. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest. 1995 Jun;95(6):2783–2789. doi: 10.1172/JCI117982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Deibler G. E., Martenson R. E., Kies M. W. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem. 1972;2(2):139–165. doi: 10.1080/00327487208061467. [DOI] [PubMed] [Google Scholar]
  12. Finkelman F. D., Madden K. B., Morris S. C., Holmes J. M., Boiani N., Katona I. M., Maliszewski C. R. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol. 1993 Aug 1;151(3):1235–1244. [PubMed] [Google Scholar]
  13. Hill R. A., Flick-Smith H. C., Dye S., Pell J. M. Actions of an IGF-I-enhancing antibody on IGF-I pharmacokinetics and tissue distribution: increased IGF-I bioavailability. J Endocrinol. 1997 Jan;152(1):123–130. doi: 10.1677/joe.0.1520123. [DOI] [PubMed] [Google Scholar]
  14. Howell M. D., Winters S. T., Olee T., Powell H. C., Carlo D. J., Brostoff S. W. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science. 1989 Nov 3;246(4930):668–670. doi: 10.1126/science.2814489. [DOI] [PubMed] [Google Scholar]
  15. Kolaczynski J. W., Caro J. F. Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks. Ann Intern Med. 1994 Jan 1;120(1):47–55. doi: 10.7326/0003-4819-120-1-199401010-00009. [DOI] [PubMed] [Google Scholar]
  16. Komoly S., Hudson L. D., Webster H. D., Bondy C. A. Insulin-like growth factor I gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1894–1898. doi: 10.1073/pnas.89.5.1894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997 Feb 27;336(9):633–640. doi: 10.1056/NEJM199702273360907. [DOI] [PubMed] [Google Scholar]
  18. Lehmann P. V., Forsthuber T., Miller A., Sercarz E. E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 1992 Jul 9;358(6382):155–157. doi: 10.1038/358155a0. [DOI] [PubMed] [Google Scholar]
  19. Lewis M. E., Neff N. T., Contreras P. C., Stong D. B., Oppenheim R. W., Grebow P. E., Vaught J. L. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol. 1993 Nov;124(1):73–88. doi: 10.1006/exnr.1993.1177. [DOI] [PubMed] [Google Scholar]
  20. Lindsey J. W., Steinman L. Competitive PCR quantification of CD4, CD8, ICAM-1, VCAM-1, and MHC class II mRNA in the central nervous system during development and resolution of experimental allergic encephalomyelitis. J Neuroimmunol. 1993 Nov-Dec;48(2):227–234. doi: 10.1016/0165-5728(93)90196-6. [DOI] [PubMed] [Google Scholar]
  21. Liu X., Yao D. L., Bondy C. A., Brenner M., Hudson L. D., Zhou J., Webster H. D. Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis. Mol Cell Neurosci. 1994 Oct;5(5):418–430. doi: 10.1006/mcne.1994.1052. [DOI] [PubMed] [Google Scholar]
  22. Liu X., Yao D. L., Webster H. Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Mult Scler. 1995 Apr;1(1):2–9. doi: 10.1177/135245859500100102. [DOI] [PubMed] [Google Scholar]
  23. Martin R., McFarland H. F., McFarlin D. E. Immunological aspects of demyelinating diseases. Annu Rev Immunol. 1992;10:153–187. doi: 10.1146/annurev.iy.10.040192.001101. [DOI] [PubMed] [Google Scholar]
  24. McMorris F. A., Smith T. M., DeSalvo S., Furlanetto R. W. Insulin-like growth factor I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci U S A. 1986 Feb;83(3):822–826. doi: 10.1073/pnas.83.3.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Moore G. R., Traugott U., Farooq M., Norton W. T., Raine C. S. Experimental autoimmune encephalomyelitis. Augmentation of demyelination by different myelin lipids. Lab Invest. 1984 Oct;51(4):416–424. [PubMed] [Google Scholar]
  26. Mozell R. L., McMorris F. A. Insulin-like growth factor I stimulates oligodendrocyte development and myelination in rat brain aggregate cultures. J Neurosci Res. 1991 Oct;30(2):382–390. doi: 10.1002/jnr.490300214. [DOI] [PubMed] [Google Scholar]
  27. Pell J. M., Flick-Smith H. C., Dye S., Hill R. A. Further characterisation of an IGF-I enhancing antibody: actions on IGF-I-induced hypoglycaemia and interaction with the analogue LR3IGF-I. Prog Growth Factor Res. 1995;6(2-4):367–375. doi: 10.1016/0955-2235(95)00023-2. [DOI] [PubMed] [Google Scholar]
  28. Pettinelli C. B., McFarlin D. E. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol. 1981 Oct;127(4):1420–1423. [PubMed] [Google Scholar]
  29. Racke M. K., Bonomo A., Scott D. E., Cannella B., Levine A., Raine C. S., Shevach E. M., Röcken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med. 1994 Nov 1;180(5):1961–1966. doi: 10.1084/jem.180.5.1961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Racke M. K., Dhib-Jalbut S., Cannella B., Albert P. S., Raine C. S., McFarlin D. E. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol. 1991 May 1;146(9):3012–3017. [PubMed] [Google Scholar]
  31. Reder A. T., Thapar M., Jensen M. A. A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease. Neurology. 1994 Dec;44(12):2289–2294. doi: 10.1212/wnl.44.12.2289. [DOI] [PubMed] [Google Scholar]
  32. Reinhardt R. R., Bondy C. A. Insulin-like growth factors cross the blood-brain barrier. Endocrinology. 1994 Nov;135(5):1753–1761. doi: 10.1210/endo.135.5.7525251. [DOI] [PubMed] [Google Scholar]
  33. Roth G. A., Jorgensen V. H., Bornstein M. B. Effect of insulin, proinsulin and pancreatic extract on myelination and remyelination in organotypic nerve tissue in culture. J Neurol Sci. 1985 Dec;71(2-3):339–350. doi: 10.1016/0022-510x(85)90072-3. [DOI] [PubMed] [Google Scholar]
  34. Svetić A., Finkelman F. D., Jian Y. C., Dieffenbach C. W., Scott D. E., McCarthy K. F., Steinberg A. D., Gause W. C. Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J Immunol. 1991 Oct 1;147(7):2391–2397. [PubMed] [Google Scholar]
  35. Tapson V. F., Boni-Schnetzler M., Pilch P. F., Center D. M., Berman J. S. Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro. J Clin Invest. 1988 Sep;82(3):950–957. doi: 10.1172/JCI113703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Urban J. L., Kumar V., Kono D. H., Gomez C., Horvath S. J., Clayton J., Ando D. G., Sercarz E. E., Hood L. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell. 1988 Aug 12;54(4):577–592. doi: 10.1016/0092-8674(88)90079-7. [DOI] [PubMed] [Google Scholar]
  37. Vandenbark A. A., Hashim G., Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature. 1989 Oct 12;341(6242):541–544. doi: 10.1038/341541a0. [DOI] [PubMed] [Google Scholar]
  38. Yao D. L., Liu X., Hudson L. D., Webster H. D. Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6190–6194. doi: 10.1073/pnas.92.13.6190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Yao D. L., West N. R., Bondy C. A., Brenner M., Hudson L. D., Zhou J., Collins G. H., Webster H. D. Cryogenic spinal cord injury induces astrocytic gene expression of insulin-like growth factor I and insulin-like growth factor binding protein 2 during myelin regeneration. J Neurosci Res. 1995 Apr 1;40(5):647–659. doi: 10.1002/jnr.490400510. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES